NASDAQ · VERV
Healthcare · Biotechnology
$11.13
Up+$0.03 (+0.27%)
Updated Aug 16, 2026, 8:04 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
VERV does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning VERV.
VERV research
Company profile and research snapshot.
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 27, 2025 | BMO Capital | Market Perform | — |
| Jun 18, 2025 | LifeSci Capital | Market Perform | — |
| Jun 18, 2025 | HC Wainwright & Co. | Neutral | — |
| Jun 18, 2025 | Jefferies | Hold | — |
| Jun 17, 2025 | William Blair | Market Perform | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Jun 20, 2025
Halper Sadeh LLC, an investor rights law firm, is investigating several companies for potential violations of federal securities laws and/or breaches of fiduciary duties to shareholders related to proposed mergers and acquisitions.
Benzinga · Jun 17, 2025
Eli Lilly has agreed to acquire Verve Therapeutics, a clinical-stage company developing gene editing medicines for cardiovascular disease. The $1.3 billion deal offers a significant premium for Verve's shareholders.
GlobeNewswire Inc. · May 28, 2025
Verve Therapeutics reported positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102, demonstrating dose-dependent decreases in blood LDL-C and PCSK9 with a mean reduction in LDL-C of 53%.
The Motley Fool · Apr 18, 2025
Verve Therapeutics' stock price jumped 40% this week after the company published positive initial data from a phase 1b clinical trial of its drug VERVE-102, which targets a genetic disorder that causes high cholesterol levels. Several analysts raised their price targets for the stock, with one even upgrading it to a buy recommendation.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning VERV.
No results
No recent SID articles mention VERV.
